$OSG

Refiners, Not Consumers, Are Biggest Winners From Jones Act Waiver, OSG CEO Says

Overseas Shipholding Group CEO Sam Norton said the Trump emergency Jones Act waiver has benefited U.S. refiners more than consumers, citing rising 3:2:1 crack spreads from about 27% in early 2026 to ~45% in early June and 70%-75% recently. He noted foreign-flag tankers are doing domestic voyages while U.S.-flag ships stay idle. The waiver expires Aug. 16.

Original reporting
Published Jul 14, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Refiners, Not Consumers, Are Biggest Winners From Jones Act Waiver, OSG CEO Says — source image
Decision brief

The 30-second read

$OSGBearishLow
01

Why it matters

The CEO’s analysis argues the waiver has not reduced gasoline or diesel prices and instead coincided with higher refining profitability, while U.S.-flag vessels remain idle as foreign-flag ships perform domestic voyages.

02

Market read

Policy-driven shipping routing under the Jones Act waiver is positioned as a utilization and competitive issue for U.S.-flag tanker operators, with a clear Aug. 16 decision point.

03

What to watch

The article does not quantify OSG’s direct revenue or contract exposure to waiver-driven routing, and it relies on a CEO commentary rather than new company filings or guidance.

Relevance 4/10Novelty 4/10Timing: Ahead of the Aug. 16 deadline to let the emergency Jones Act waiver expire.

Background

The Trump administration invoked Section 501 of the Merchant Marine Act in March to allow approved foreign-flag vessels to carry certain petroleum products between U.S. ports, with the emergency waiver set to expire Aug. 16.

Company-level read

Ticker impact

$OSGBearishMedium confidence
Context

Overseas Shipholding Group CEO Sam Norton argues the ongoing Jones Act waiver has shifted domestic voyages to foreign-flag tankers, sidelining U.S.-flag operators.

Expected impact

Near-term sentiment risk for OSG if the waiver is extended past Aug. 16, with potential upside if it expires and U.S.-flag demand returns.

Evidence & confidence

The piece is commentary, but it cites MARAD approval activity (170 voyages as of July 13) and highlights U.S.-flag idling, which can affect utilization expectations for OSG.

Market effects

Could increase scrutiny of Jones Act waiver policy, affecting demand expectations for U.S.-flag tanker operators and potentially shifting freight economics toward foreign-flag capacity.

U.S. Gulf Coast refining and port activity may see continued domestic cargo routing by foreign-flag vessels, influencing local tanker utilization.

Iran/Strait of Hormuz risk is the stated trigger for the waiver, so any escalation or de-escalation can change waiver justification and shipping patterns.

Counterpoint

Even if refiners capture margins, the waiver may still be necessary to prevent supply disruptions; any consumer-price pass-through could lag or be offset by other market factors.

Key entities

  • Overseas Shipholding Group

    U.S.-flag tanker operator whose CEO argues the Jones Act waiver has shifted domestic voyages away from U.S.-flag vessels.

  • MARAD

    U.S. Maritime Administration, cited as continuing to approve domestic voyages under the waiver (170 approved voyages as of July 13).

  • Seafarers International Union

    Protested the continued operation of a Chinese-flagged tanker performing coastwise voyages.

  • Marathon Petroleum

    Protest location referenced, where a tanker was preparing another domestic shipment.

Related articles

$OSGMedAI 8/10

Octave Specialty Group (OSG) Q2 2026 Earnings Call Transcript

Octave Specialty Group (OSG) reported Q2 2026 revenue of $83.0 million, up 51% year over year, driven by its Insurance Distribution segment. Net loss attributable to shareholders was $14.4 million, and adjusted EBITDA was $3.7 million. Management raised 2026 distribution organic growth to 25%+ and adjusted EBITDA to $45 million, but lowered adjusted EPS guidance to $0.15-$0.20 and Everspan adjusted EBITDA to $6 million.

$OSGMedAI 8/10

OSG Q2 Earnings Miss Estimates, Revenues Beat on Distribution Growth

Octave Specialty Group (OSG) reported Q2 2026 adjusted loss of 4 cents per share, narrower than a year ago but worse than the Zacks estimate of a 1-cent loss. Revenues rose 51% to $83 million. Insurance Distribution revenue grew 77% to $58.4 million. Management raised 2026 Insurance Distribution outlook, while cutting Everspan EBITDA guidance to $6 million. The article also cites Q2 results for SIGI, AXS, and CINF.

$OSGMed

OCTAVE SPECIALTY GROUP INC (OSG): Results of Operations and Financial Condition

OCTAVE SPECIALTY GROUP INC (OSG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Octave Specialty Group Reports Second Quarter 2026 Results • Insurance Distribution Segment ◦ Total revenue grew 77% to $58 million ◦ Organic revenue growth equaled 44% ◦ Ne t loss to Shareholders totaled $(4) million , compared to $(8) million in 2Q25 ◦ Adjusted EBI

$METAMedAI 9/10

An $18bn settlement – and Zuckerberg barely blinked. The tech titans must be stripped of their power, and soon | Jonathan Freedland

Meta agreed to an $18bn settlement with 29 US states over claims its platforms harmed children. Despite the large sum, Meta's stock rose, as the payment is manageable over 10 years. The settlement includes usage restrictions for young users but no admission of liability. Critics argue the deal does not address core issues like the recommendation algorithm or global impact.

$GILDHighAI 9/10

FDA approves smallest single-pill HIV regimen, Bixlenvo

The FDA approved Gilead Sciences' Bixlenvo, a single-pill HIV therapy combining bictegravir and lenacapavir. It is the smallest daily regimen for virologically suppressed adults on complex treatments. Gilead claims it will benefit aging patients and those with resistance or tolerability issues. Approval was based on ARTISTRY-1 and ARTISTRY-2 trial data.